J&J presses on with drug to prevent premature ejaculation

07/10/2007 | Wall Street Journal (free content), The

Other drugmakers have abandoned their search for a drug to prevent premature ejaculation, but Johnson & Johnson, whose first try was rejected by the FDA, is still in the hunt. The company intends to test its dapoxetine outside the U.S. and file for regulatory approval in Europe and Canada later this year. The FDA declined to approve it in 2005, questioning its medical benefit.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI